Aims: We aimed to investigate the incidence rates and risk factors for different subgroups of central neck lymph node (LN) metastasis (prelaryngeal, ipsilateral paratracheal, pretracheal, and contralateral paratracheal) in unilateral papillary thyroid carcinoma (PTC) patients with clinically negative neck nodes (cN₀). Methods: We evaluated 184 patients from 2007 to 2009. The relationships between different subgroups of LN metastasis and clinical pathological factors were analyzed. Results: The incidence rates of different central LN metastases were diverse. Multivariate analysis indicated that lymphovascular invasion, perithyroidal invasion, and tumor size were risk factors for ipsilateral paratracheal central LN metastasis; tumor size was an independent risk factor for pretracheal central LN metastasis, and pretracheal or/and ipsilateral paratracheal central LN metastasis were risk factors for contralateral paratracheal central LN metastasis. Conclusion: The extent of elective central LN dissection (CLND) should be decided based on different clinical pathological factors in cN₀ PTC patients. Moreover, elective prelaryngeal CLND may be unnecessary.

Keywords:
Papillary thyroid carcinoma, Central lymph node, Metastasis, Risk factors
1.
Pearce EN, Braverman LE: Papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab 2004;89:3710-3712.
2.
Machens A, Holzhausen HJ, Dralle H: Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg 2004;139:43-45.
3.
Qubain SW, Nakano S, Baba M, Takao S, Aikou T: Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 2002;131:249-256.
4.
Cooper DS, Doherty GM, Haugen BR, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
5.
White ML, Gauger PG, Doherty GM: Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007;31:895-904.
6.
Henry JF, Gramatica L, Denizot A, et al: Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998;383:167-169.
7.
Pereira JA, Jimeno J, Miquel J, Kvachenyuk A, Puccini M, Defechereux T: Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 2005;138:1095-1100, discussion 1100-1101.
8.
Kim MK, Mandel SH, Baloch Z, Livolsi VA, Langer JE, Didonato L, Fish S, Weber RS: Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg 2004;130:1214-1216.
9.
Chisholm EJ, Kulinskaya E, Tolley NS: Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 2009;119:1135-1139.
10.
Simon D, Goretzki PE, Witte J, Roher HD: Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg 1996;20:860-866.
11.
Tisell LE, Nilsson B, Molne J, Hansson G, Fjalling M, Jansson S, Wingren U: Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996;20:854-859.
12.
Fritze D, Doherty GM: Surgical management of cervical lymph nodes in differentiated thyroid cancer. Otolaryngol Clin North Am 2010;43:285-300.
13.
Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, Randolph GW, Stack BC Jr, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R: Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19:1153-1158.
14.
Sugitani I, Fujimoto Y, Yamada K, Yamamoto N: Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg 2008;32:2494-2502.
15.
Mazzaferri EL, Doherty GM, Steward DL: The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 2009;19:683-689.
16.
Shen WT, Ogawa L, Ruan D, Suh I, Kebebew E, Duh QY, Clark OH: Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg 2010;145:272-275.
17.
Shindo M, Stern A: Total thyroidectomy with and without selective central compartment dissection: a comparison of complication rates. Arch Otolaryngol Head Neck Surg 2010;136:584-587.
18.
Hughes DT, Doherty GM: Central neck dissection for papillary thyroid cancer. Cancer Control 2011;18:83-88.
19.
Grebe SK, Hay ID: Thyroid cancer nodal metastasis: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:43-63.
20.
Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L: Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 2006;140:1000-1005, discussion 1005-1007.
21.
Son YI, Jeong HS, Baek CH, Chung MK, Ryu J, Chung JH, So YK, Jang JY, Choi J: Extent of prophylactic lymph node dissection in the central neck area of the patients with papillary thyroid carcinoma: comparison of limited versus comprehensive lymph node dissection in a 2-year safety study. Ann Surg Oncol 2008;15:2020-2026.
22.
Low TH, Delbridge L, Sidhu S, Learoyd D, Robinson B, Roach P, Sywak M: Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol 2008;15:2827-2832.
23.
Roh JL, Park JY, Park CI: Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 2007;245:604-610.
24.
Cavicchi O, Piccin O, Caliceti U, De Cataldis A, Pasquali R, Ceroni AR: Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol Head Neck Surg 2007;137:654-658.
25.
Goropoulos A, Karamoshos K, Christodoulou A, Ntitsias T, Paulou K, Samaras A, Xirou P, Efstratiou I: Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg 2004;28:1275-1281.
26.
Hasney CP, Amedee RG: What is the appropriate extent of lateral neck dissection in the treatment of metastatic well-differentiated thyroid carcinoma? Laryngoscope 2010;120:1716-1717.
27.
Koo BS, Choi EC, Yoon YH, Kim DH, Kim EH, Lim YC: Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg 2009;249:840-844.
28.
Lee KE, Chung IY, Kang E, Koo DH, Kim KH, Kim SW, Youn YK, Oh SK: Ipsilateral and contralateral central lymph node metastasis in papillary thyroid cancer: patterns and predictive factors of nodal metastasis. Head Neck 2013;35:672-676.
29.
Roh JL, Kim JM, Park CI: Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Ann Surg Oncol 2011;18:2245-2250.
30.
Isaacs JD, McMullen TP, Sidhu SB, Sywak MS, Robinson BG, Delbridge LW: Predictive value of the delphian and level VI nodes in papillary thyroid cancer. ANZ J Surg 2010;80:834-838.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.